Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2019 Sep:47:2-3.
doi: 10.1016/j.ebiom.2019.08.049. Epub 2019 Sep 6.

Management of metastatic renal cell carcinoma: The complexity of choice

Jacqueline T Brown  1 , Mehmet Asim Bilen  2
Affiliations
Comment

Management of metastatic renal cell carcinoma: The complexity of choice

Jacqueline T Brown et al. EBioMedicine. 2019 Sep.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Wang J. Role of immune checkpoint inhibitor-based therapies for metastatic renal cell carcinoma in the first-line setting: a systematic review and Bayesian network analysis. EBioMedicine. 2019 - PMC - PubMed
    1. Motzer R.J. Nivolumab plus Ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277–1290. - PMC - PubMed
    1. Rini B.I. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1116–1127. - PubMed
    1. Motzer R.J. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1103–1115. - PMC - PubMed
    1. Choueiri T.K. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the Alliance A031203 CABOSUN trial. J Clin Oncol. 2017;35(6):591–597. - PMC - PubMed